NEW YORK, Jan. 7 (GenomeWeb News) -- PTC Therapeutics of South Plainfield, NJ, announced today the closing of a $35 million Series E round of funding led by CSFB Private Equity and HBM Bioventures.

Additional investors included Bay City Capital, Delphi Ventures, Hansa Special Opportunities Fund Ltd., HealthCap, Novartis BioVentures, Novo A/S, POSCO BioVentures and Vulcan Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.